ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Senate Kills Construction Reprograming Plan; NCI To Seek Limit On Future Grant Applications

March 18, 1977

Clinical Trials Approved By NCI CTEP Last Month

February 25, 2011

In Brief: ACS Asks Removal Of Dollar Authorization Levels; FDA May Overrule Advisors On Estramustine

November 23, 1979

Biopsy System Effective In Removing Benign Breast Masses, Study Finds

May 28, 2004

In Brief: Reynolds Retires “Joe Camel” advertising; Slaga Moves Lab To MC Cancer Center

July 18, 1997

Tarceva-Induced Rash Strongly Associated With Longer Survival, Sponsor Finds

July 27, 2007